company? Let’s change
that.
The Public Health Company (PHC Global) is developing the first global biosecurity platform to provide enterprises a SaaS-enabled service for the management of bio-risks. PHC combines world-class expertise with cutting edge technology to be the global solution to enterprise risk management. PHC focuses on intersecting physical world threats across diverse use-cases to deliver actionable and predictive intelligence that enables dynamic risk management with unprecedented speed and scale
Pardes is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. By capitalizing on emerging patient-friendly innovations from telehealth to new at-home diagnostic tools, Pardes is cultivating and harvesting the fruits of systemic change. We are on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
Third Harmonic Bio is a clinical-stage biopharmaceutical company developing a highly selective, oral KIT inhibitor for treatment of dermal, respiratory and gastrointestinal inflammatory diseases. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with mast-cell mediated inflammatory diseases. By inhibiting KIT, we believe we can provide broad symptomatic relief to patients with a range of disorders, including chronic spontaneous urticaria and severe asthma
Parachute is a new kind of plasma donation company that allows individuals to earn money while creating life-saving medicine. Plasma is used to create medicine that treats chronic illnesses, including immune disorders, liver disease, bleeding disorders, and cancer. Right now, there’s a severe plasma shortage, which is impacting patients’ access to these life-saving treatments
Vow is a cultured meat company, founded and operated in Sydney, Australia. We’re a multidisciplinary team of scientists, technologists and designers, all working together to make sustainable food both irresistible and available to billions of people.
iCarbonX is a technology company that is changing how people monitor and understand their health status and optimize their lives. We are building the platform and tools for digitizing, analyzing, and understanding life, and delivering intelligent products and applications—designed for every aspect and stage of life—to help everyone make smarter choices, every day. We’re inspired by every life on this planet, and by a commitment to apply intelligence not just to data, but to the ethical use of that data. Our mission is to bring people together to improve the human condition. We believe we must go beyond genetics to help people understand not just who they are, but how they are. We’re answering the “how” by combining biological and behavioral data with artificial intelligence in a network where people can learn from their own experience and from others like them, creating a global map of human health across cultures and continents that delivers new information and new choices, for life.
At Inato, we’re on a mission to accelerate the pace of medical innovation by bringing clinical research to each and every patient, regardless of who they are and where they live. Our platform, made to connect community-based research centers to trials across the globe, aims to create greater visibility, access, and engagement across a more diverse population of doctors and their patients.
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for autoimmune diseases. We are leveraging the extensive drug development expertise of our team to acquire best-in-class assets against compelling targets, and applying them to disease areas with significant unmet need. Timberlyne’s lead program, CM313, is an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38. By targeting CD38, highly expressed on plasma cells, NK cells, and other immune cells, CM313 can modulate multiple arms of the immune system leading to both rapid and durable responses across a range of autoimmune diseases. CM313 has been tested in numerous disease states including Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma. Timberlyne plans to develop CM313 across a broad range of autoimmune indications. Launched in 2024, Timberlyne has raised $180 million from leading life sciences investors.
Motitus is a consulting firm specializing in biotechnology, pharmaceuticals, healthcare, life sciences, and health tech, working with ambitious leaders. We bridge the gap between thinking and implementation with extraordinary impact. We deliver mission projects that transform your business into state-of-the-art for the industry. The word Motitus carries a compelling narrative that resonates deeply within the realms of healthcare and innovation. The name itself, derived from the Latin word for "movement," encapsulates the essence of progress, dynamism, and transformation—qualities that are vital in the fast-evolving landscape of health and medicine. From its inception, Motitus aimed to be more than just a consultancy; it sought to be a catalyst for change. The brand's identity is built around the concept of movement, representing the fluidity and adaptability required in modern healthcare. Whether it’s helping a pharmaceutical company navigate regulatory hurdles or assisting a biotech startup in bringing its product to market, Motitus embodies the spirit of progress and agility.
ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.
Normunity, Inc., is a biotechnology company creating a new class of precision immuno-oncology medicines, called immune normalizers, that target novel mechanisms that free the body’s normal immunity against cancer. Based on an ongoing, interactive academic-biotech alliance with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is targeting newly-discovered mechanisms of immune disruption in cancer based on proprietary discovery platforms that elucidate the complex interactions between human cancer and the immune system. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. Normunity is located in Boston, Mass. and West Haven, Conn
Work Your Passion. Live Your Purpose.